Group 1 - The core point of the article is that Bohan Biotech (06955) has seen its stock price increase by over 4% following the completion of patient enrollment in the Phase III clinical trial for its drug BA1104 (Nivolumab injection) in China [1] - As of the report, Bohan Biotech's stock is trading at 10.48 HKD with a transaction volume of 45.98 million HKD [1] - BA1104 is the first biosimilar of Opdivo (Nivolumab) to enter Phase III clinical trials in China, indicating a significant milestone for the company [1] Group 2 - The Phase III clinical trial for BA1104 is a randomized, double-blind, multi-center study aimed at comparing the efficacy, safety, and immunogenicity of BA1104 combined with chemotherapy against Opdivo in patients with advanced or metastatic esophageal squamous cell carcinoma [1] - The results from the completed Phase I clinical trial show that BA1104 is highly comparable to Opdivo in terms of pharmacokinetics, safety, and immunogenicity, achieving all study endpoints [1] - The research results from the Phase I trial have been published in the international journal "BioDrugs," further validating the drug's development progress [1]
港股异动 | 博安生物(06955)涨超4% 纳武利尤单抗中国Ⅲ期临床试验完成所有患者入组